Omada Health(NASDAQ) OMDA

Omada Health, Inc. helps people manage long-term illness using digital tools. Its medical teams provide extra support between regular doctor visits. These services help patients take care of themselves from home.

What Omada Offers

• Clinical Services: Virtual care for cardiometabolic and physical therapy conditions; accounts for 92% of revenue for the three months ended June 30, 2026.
• GLP-1 Care Tracks: Support programs for patients using specialized weight-loss medications.
• Behavioral Health: Mental health support integrated into all primary chronic care programs.
• Connected Hardware: Cellular scales and glucose meters provided to members; accounts for 8% of revenue for the three months ended June 30, 2026.

Recent Milestones

• Completed an initial public offering on June 9, 2025, raising approximately $151.6 million.
• Expanded into musculoskeletal care and behavioral health support to manage multiple chronic conditions.
• Repaid $31.4 million in total debt on July 31, 2025, using proceeds from the public offering.
• Introduced prescribing capabilities for anti-obesity medications as an extension of support offerings.

Bridging the Care Gap

Omada uses a "Between-Visit Care" model that connects medical teams with patients through a proprietary technology platform. The company has served more than 2 million members since launch. Five key partners generated 79% of revenue during the three months ended June 30, 2026.

Tracking the Performance

• Total revenue was $87.8 million for the three months ended June 30, 2026, up 43% year over year.
• Member enrollment reached 1,091,000 as of June 30, 2026, compared to 752,000 as of June 30, 2025.
• Gross profit hit $63.8 million for the three months ended June 30, 2026, up 58% year over year.
• Net income hit $5.3 million for the three months ended June 30, 2026, reversing a prior-year loss of $5.3 million.

Evolution Toward Growth

Omada has transitioned from a single diabetes prevention program to a multi-condition virtual care provider. Its shift toward integrated technology and specialized medication support has allowed it to scale while improving profit margins.